E
Aspire Biopharma Holdings, Inc. ASBP
$0.4871 -$0.0205-4.04% NASDAQ
Recommendation
Prev Close
$0.4871
Volume
81,166
Avg Vol (90D)
338,522
Market Cap
$22.66M
Dividend & Yield
--
52-Week Range
$0.4011 - $15.80
P/E (TTM)
--
EPS (TTM)
-$0.0011
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
4/16/2025 - Globe Newswire
Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream
4/15/2025 - Globe Newswire
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
4/14/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, ...
4/14/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
4/14/2025 - Accesswire
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance ...
4/11/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance ...
4/11/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
4/11/2025 - Accesswire
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral ...
4/9/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral ...
4/9/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
4/9/2025 - Accesswire
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice ("GMP") Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
3/20/2025 - Accesswire
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. ...
3/13/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
3/13/2025 - Accesswire
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
3/11/2025 - Newsfile Corp. - News Releases
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
3/3/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
3/3/2025 - Accesswire
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, ...
2/25/2025 - GuruFocus
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
2/25/2025 - Accesswire
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
2/20/2025 - Accesswire
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
2/20/2025 - Accesswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$579.70K
Net Income (TTM)
-$581.20K
Balance Sheet
Total Assets (Q)
$184.00K
Total Debt (Q)
$853.10K
Total Liabilities (Q)
$985.60K
Book Value Per Share (Q)
-$0.0018
Cash Flow
Cash from Operations (TTM)
-$403.50K
Cash from Investing (TTM)
-$75.80K
Cash from Financing (TTM)
$481.30K
Net Change in Cash (TTM)
$1.90K
Filings
Filing Date
Wednesday, January 8, 2025
Period Date
Monday, September 30, 2024
Next Filing
Week of Sep 1 and 5 (est)
Price History
Loading...
Beta
1.59
7-Day Total Return
-11.68%
30-Day Total Return
-21.44%
60-Day Total Return
-95.87%
90-Day Total Return
-95.74%
Year to Date Total Return
-95.76%
1-Year Total Return
-95.63%
2-Year Total Return
-95.37%
3-Year Total Return
-95.12%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $0.4011
52-week High
Feb 12, 2025 - $15.80
Valuation
Market Cap
$22.66M - Nano Cap
Enterprise Value
$23.49M
Price/Sales (TTM)
--
Price/Book (Q)
-270.61
Dividends and Shares
Shares Outstanding
443.32M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
aspirebiolabs.com
Phone Number
415 592 7399
Address
194 Candelero Drive
Humacao, PR 00791
Country
United States
Year Founded
2021
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United... more
NASDAQ 04/25/2025 3:59PM Eastern Quotes delayed